2021 Year in Review: OPDP Enforcement Actions Involving Prescription and Biological Products | Faegre Drinker Biddle & Reath LLP
The Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) issued a total of six letters in 2021 — four Untitled Letters and two Warning Letters — to pharmaceutical...
Source: jdsupra.com